Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Immune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overa...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-12361-9 |
id |
doaj-e4c8bc25921749a9be4db41b69a5d41b |
---|---|
record_format |
Article |
spelling |
doaj-e4c8bc25921749a9be4db41b69a5d41b2021-05-11T11:48:26ZengNature Publishing GroupNature Communications2041-17232019-09-011011610.1038/s41467-019-12361-9Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li0Kevin Bullock1Carino Gurjao2David Braun3Sachet A. Shukla4Dominick Bossé5Aly-Khan A. Lalani6Shuba Gopal7Chelsea Jin8Christine Horak9Megan Wind-Rotolo10Sabina Signoretti11David F. McDermott12Gordon J. Freeman13Eliezer M. Van Allen14Stuart L. Schreiber15F. Stephen Hodi16William R. Sellers17Levi A. Garraway18Clary B. Clish19Toni K. Choueiri20Marios Giannakis21Department of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardBristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbDepartment of Medical Oncology, Dana-Farber Cancer InstituteBeth Israel Deaconess Medical CenterDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of MIT and HarvardDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteImmune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overall survival.https://doi.org/10.1038/s41467-019-12361-9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haoxin Li Kevin Bullock Carino Gurjao David Braun Sachet A. Shukla Dominick Bossé Aly-Khan A. Lalani Shuba Gopal Chelsea Jin Christine Horak Megan Wind-Rotolo Sabina Signoretti David F. McDermott Gordon J. Freeman Eliezer M. Van Allen Stuart L. Schreiber F. Stephen Hodi William R. Sellers Levi A. Garraway Clary B. Clish Toni K. Choueiri Marios Giannakis |
spellingShingle |
Haoxin Li Kevin Bullock Carino Gurjao David Braun Sachet A. Shukla Dominick Bossé Aly-Khan A. Lalani Shuba Gopal Chelsea Jin Christine Horak Megan Wind-Rotolo Sabina Signoretti David F. McDermott Gordon J. Freeman Eliezer M. Van Allen Stuart L. Schreiber F. Stephen Hodi William R. Sellers Levi A. Garraway Clary B. Clish Toni K. Choueiri Marios Giannakis Metabolomic adaptations and correlates of survival to immune checkpoint blockade Nature Communications |
author_facet |
Haoxin Li Kevin Bullock Carino Gurjao David Braun Sachet A. Shukla Dominick Bossé Aly-Khan A. Lalani Shuba Gopal Chelsea Jin Christine Horak Megan Wind-Rotolo Sabina Signoretti David F. McDermott Gordon J. Freeman Eliezer M. Van Allen Stuart L. Schreiber F. Stephen Hodi William R. Sellers Levi A. Garraway Clary B. Clish Toni K. Choueiri Marios Giannakis |
author_sort |
Haoxin Li |
title |
Metabolomic adaptations and correlates of survival to immune checkpoint blockade |
title_short |
Metabolomic adaptations and correlates of survival to immune checkpoint blockade |
title_full |
Metabolomic adaptations and correlates of survival to immune checkpoint blockade |
title_fullStr |
Metabolomic adaptations and correlates of survival to immune checkpoint blockade |
title_full_unstemmed |
Metabolomic adaptations and correlates of survival to immune checkpoint blockade |
title_sort |
metabolomic adaptations and correlates of survival to immune checkpoint blockade |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2019-09-01 |
description |
Immune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overall survival. |
url |
https://doi.org/10.1038/s41467-019-12361-9 |
work_keys_str_mv |
AT haoxinli metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT kevinbullock metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT carinogurjao metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT davidbraun metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT sachetashukla metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT dominickbosse metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT alykhanalalani metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT shubagopal metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT chelseajin metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT christinehorak metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT meganwindrotolo metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT sabinasignoretti metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT davidfmcdermott metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT gordonjfreeman metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT eliezermvanallen metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT stuartlschreiber metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT fstephenhodi metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT williamrsellers metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT leviagarraway metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT clarybclish metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT tonikchoueiri metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade AT mariosgiannakis metabolomicadaptationsandcorrelatesofsurvivaltoimmunecheckpointblockade |
_version_ |
1721446014666145792 |